Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 3/20 | 0.33 |
| ▸ | MC3R | P41968 | 1/20 | 0.31 |
| ▸ | MC1R | Q01726 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4022565 | 0.87 | L3MBTL1 (0.30) | — | |
| SCHEMBL4772489 | 0.86 | NPSR1 (0.33) | — | |
| SCHEMBL4021646 | 0.86 | MC4R (0.36) | MC4RMC3RMC1RKCNH2KDM2B | |
| SCHEMBL4021615 | 0.83 | HCRTR2 (0.31) | — | |
| SCHEMBL4022123 | 0.82 | RORC (0.41) | MC4R | |
| SCHEMBL4028221 | 0.82 | KDM2B (0.32) | MC4RKDM2B | |
| SCHEMBL4778094 | 0.82 | KDM2B (0.32) | KDM2B | |
| SCHEMBL4022033 | 0.82 | KDM2B (0.32) | MC4RKDM2B | |
| SCHEMBL4774163 | 0.81 | KDM2B (0.31) | KDM2B | |
| SCHEMBL4028913 | 0.81 | MC4R (0.30) | MC4RKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572814-B2 | 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds | CYTOKINETICS, INCORPORATED (US) | 2009-08-11 | — | — | US | disclosed |
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | TP53, VHL, RB1 | MC4R 3874/4885MC3R 3395/4885MC1R 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.